ConductScience.org, home

Paper · 40407381

References22

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
129282508A Nomogram to Predict Prognosis in Malignant Pleural Mesothelioma.World J Surg2018https://conductscience.org/library/papers/29282508PubMed
232206576Immunotherapy for mesothelioma: a critical review of current clinical trials and future perspectives.Transl Lung Cancer Res2020https://conductscience.org/library/papers/32206576PubMed
336841541Brief Report: Canadian Cancer Trials Group IND.227: A Phase 2 Randomized Study of Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma (NCT02784171).J Thorac Oncol2023https://conductscience.org/library/papers/36841541PubMed
433836153Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study.Lancet Respir Med2021https://conductscience.org/library/papers/33836153PubMed
512860938Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.J Clin Oncol2003https://conductscience.org/library/papers/12860938PubMed
631487687Small Bowel Adenocarcinoma, Version 1.2020, NCCN Clinical Practice Guidelines in Oncology.J Natl Compr Canc Netw2019https://conductscience.org/library/papers/31487687PubMed
734036692Pembrolizumab plus pemetrexed-platinum for metastatic nonsquamous non-small-cell lung cancer: KEYNOTE-189 Japan Study.Cancer Sci2021https://conductscience.org/library/papers/34036692PubMed
835124183First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743.Ann Oncol2022https://conductscience.org/library/papers/35124183PubMed
930267842Pneumonitis in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk Factors.J Thorac Oncol2018https://conductscience.org/library/papers/30267842PubMed
1022438785Mesothelioma: a review.Ochsner J2012https://conductscience.org/library/papers/22438785PubMed
1137931632Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial.Lancet2023https://conductscience.org/library/papers/37931632PubMed
1214760119Modified RECIST criteria for assessment of response in malignant pleural mesothelioma.Ann Oncol2004https://conductscience.org/library/papers/14760119PubMed
1334589998Clinical Efficacy and Safety of Nivolumab in Japanese Patients With Malignant Pleural Mesothelioma: 3-Year Results of the MERIT Study.JTO Clin Res Rep2021https://conductscience.org/library/papers/34589998PubMed
1418434338Efficacy and safety of pemetrexed in combination with cisplatin for malignant pleural mesothelioma: a phase I/II study in Japanese patients.Jpn J Clin Oncol2008https://conductscience.org/library/papers/18434338PubMed
1517715248Dose-finding in phase I clinical trials based on toxicity probability intervals.Clin Trials2007https://conductscience.org/library/papers/17715248PubMed
1628291584Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial.Lancet Oncol2017https://conductscience.org/library/papers/28291584PubMed
1734711664JME-001 phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma.J Immunother Cancer2021https://conductscience.org/library/papers/34711664PubMed
1828239496Life Expectancy in Pleural and Peritoneal Mesothelioma.Lung Cancer Int2017https://conductscience.org/library/papers/28239496PubMed
1929342862Heterogeneous Contributing Factors in MPM Disease Development and Progression: Biological Advances and Clinical Implications.Int J Mol Sci2018https://conductscience.org/library/papers/29342862PubMed
2034750557Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial.Nat Med2021https://conductscience.org/library/papers/34750557PubMed

papers-2026-11-12-0.1.0

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/papers/v1/40407381/references